Core Insights - Idorsia Ltd has published a study on the efficacy and safety of daridorexant for treating insomnia in women during menopausal transition, highlighting its potential benefits in this demographic [1][4][8]. Group 1: Study Findings - Daridorexant 50 mg significantly improved sleep and daytime functioning compared to placebo, with improvements in wake after sleep onset (WASO) by approximately 43 minutes, latency to persistent sleep (LPS) by about 34 minutes, and self-reported total sleep time by around 75 minutes [3][9][12]. - The incidence of somnolence and fatigue was low and comparable to placebo, with no increase in next-morning sleepiness observed [3][12]. Group 2: Clinical Implications - Insomnia disorder affects about one in four women during the menopausal transition, often remaining underdiagnosed and undertreated, indicating a need for clinicians to recognize and address this condition [4][22]. - The CELESTE study, funded by the Patient-Centered Outcomes Research Institute (PCORI), will evaluate the effectiveness and safety of daridorexant among approximately 900 peri- and post-menopausal women with insomnia over a 60-month period [10][11]. Group 3: Company Commitment - Idorsia is committed to advancing the science of sleep and insomnia, providing daridorexant at no cost to support the CELESTE study [6][7]. - The company aims to challenge existing medical paradigms and develop transformative medicines, positioning itself as a leading biopharmaceutical company [29][30].